Bioevaluation of Spiro N-Propargylic β-Enaminones as Anti-Breast Cancer Agents: In Vitro and Molecular Docking Studies.


Journal

Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 14 08 2023
accepted: 12 10 2023
medline: 29 11 2023
pubmed: 15 10 2023
entrez: 14 10 2023
Statut: ppublish

Résumé

The study aimed to investigate the in vitro inhibitory activities of spiro N-propargylic β-enaminones, SPEs 1-31, against BCa cells, to perform in silico molecular docking studies to understand the nature of the interaction between the compounds and the ERα, PR, EGFR, and Her2, and to determine the ADMET and drug-likeness properties. Cytotoxic activity was investigated via MTT assay. DNA fragmentation was evaluated via ELISA assay. Cell cycle distributions were investigated by flow cytometry. Expression levels of Bcl-2, Bax, p21 and Cyclin D1 were measured by qRT-PCR and western blot analysis. Molecular docking was done using Autodock/vina software. ADMET analysis was calculated using the ADMETlab 2.0 tool. SPEs 1, 22, and 28 showed selective cytotoxic activity against all BCa cells with SI values >2. SPEs induced apoptosis and caused significant changes in Bcl-2 and Bax levels. The cell cycle was arrested at the S phase and levels of p21 and Cyclin D1 were induced in all BCa cells. Molecular docking analysis revealed that SPE1, SPE22, and SPE28 showed high binding affinities with ERα, PR, EGFR, and Her2. ADMET analysis revealed that SPEs are drug-like compounds as they obey the five rules of Lipinsky and are not toxic. Therefore, these potential anticancer compounds should be further validated by in vivo studies for their appropriate function in human health with a safety profile, and a comprehensive drug interaction study should be performed.

Identifiants

pubmed: 37837366
doi: 10.1002/cbdv.202301228
doi:

Substances chimiques

Estrogen Receptor alpha 0
Cyclin D1 136601-57-5
bcl-2-Associated X Protein 0
Antineoplastic Agents 0
Proto-Oncogene Proteins c-bcl-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202301228

Subventions

Organisme : Scientific and Technological Research Council of Turkey
ID : 114Z811
Organisme : Research Fund of Middle East Technical University
ID : GAP-103-2018-2770

Informations de copyright

© 2023 Wiley-VHCA AG, Zurich, Switzerland.

Références

H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, CA. Cancer J. Clin. 2021, 71, 209-249.
D. L. Holliday, V. Speirs, Breast. Cancer. Res. 2011, 13, 1-7.
Z. Anastasiadi, G. D. Lianos, E. Ignatiadou, H. V. Harissis, M. Mitsis, Updates. Surg. 2017, 69, 313-317.
V. Parvathaneni, N. S. Kulkarni, A. Muth, V. Gupta, Drug. Discov. Today. 2019, 24, 2076-2085.
A. S. Correia, F. Gärtner, N. Vale, Heliyon. 2021, 7, e05948.
F. Napolitano, Y. Zhao, V. M. Moreira, R. Tagliaferri, J. Kere, M. D′Amato, D. Greco, J. Cheminform. 2013, 5, 1-9.
M. Gönen, Bioinformatics. 2012, 28, 2304-2310.
R. Acharya, S. Chacko, P. Bose, A. Lapenna, S. P. Pattanayak, Sci. Rep. 2019, 9, 15743.
A. Al-Mulla, Der. Pharma. Chem. 2017, 9, 141-147.
Y. Zheng, C. M. Tice, and S. B. Singh, Bioorg. Med. Chem. Lett. 2014, 24, 3673-3682.
B. A. Dundar, M. Zora, Synth. Commun. 2022, 52, 356-367.
I. J. Amaye, R. D. Haywood, E. M. Mandzo, J. J. Wirick, P. L. Jackson-Ayotunde, Tetrahedron. 2021, 83, 131984.
R. Kaminsky, C. Schmid, R. Brun, Vitr. Mol. Toxicol. J. Basic Appl. Res. 1996, 9, 315-324.
C. Erten, B. Karaca, Y. Kucukzeybek, G. Gorumlu, E. Cengiz, M. K. Gul, H. Atmaca, S. Uzunoglu, B. Karabulut, U. A. Sanli, R. Uslu, BJU Int. 2009, 104, 107-114.
H. Atmaca, A. N. Özkan, M. Zora, Chem. Biol. Interact. 2017, 263, 28-35.
H. Atmaca, S. Uzunoglu, Eur. Cytokine Netw. 2014, 25, 1-7.
N. M. O'Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch, G. R. Hutchison, J. Cheminform. 2011, 3, 33.
G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell, A. J. Olson, J. Comput. Chem. 2009, 30, 2785-2791.
C. A. Lipinski, Drug. Discov. Today. Technol. 2004, 1, 337-341.
A. Arnaout, S. J. Robertson, G. R. Pond, H. Lee, A. Jeong, L. Ianni, L. Kroeger, J. Hilton, S. Coupland, C. Gottlieb, B. Hurley, A. McCarthy, M. Clemons, Breast. Cancer. Res. Treat. 2019, 178, 327-335.
J. Dewangan, S. Srivastava, S. Mishra, A. Divakar, S. Kumar, S. K. Rath, Biochem. Pharmacol. 2019, 164, 326-335.
M. Mittersteiner, V. P. Andrade, H. G. Bonacorso, M. A. P. Martins, N. Zanatta, European. J. Organic. Chemistry. 2020, 2020, 6405-6417.
P. Subramamiam, C. Ramasubbu, S. Athiramu, S. Arumugam, and M. Alagumuthu, Arch. Pharm. (Weinheim) 2019, 352, e1800244.
M. M. Ghorab, M. S. Alsaid, H. A. Ghabour, H. K. Fun, Asian. J. Chem. 2014, 26, 7424-7430.
T. Luker, L. Alcaraz, K. K. Chohan, N. Blomberg, D. S. Brown, R. J. Butlin, T. Elebring, A. M. Griffin, S. Guile, S. St-Gallay, B. M. Swahn, S. Swallow, M. J. Waring, M. C. Wenlock, P. D. Leeson, Bioorganic. Med. Chem. Lett. 2011, 21, 5673-5679.
K. Müller, C. Faeh, F. Diederich, Science. 2007, 317, 1881-1886.
C. Isanbor, D. O'Hagan, J. Fluor. Chemistry. 2006, 127, 303-319.
S. Goel, M. J. DeCristo, S. S. McAllister, J. J. Zhao, Trends. Cell. Biol. 2018, 28, 911-925.
M. Piezzo, S. Cocco, R. Caputo, D. Cianniello, G. D. Gioia, V. D. Lauro, G. Fusco, C. Martinelli, F. Nuzzo, M. Pensabene, M. De Laurentiis, Int. J. Mol. Sci. 2020, 21, 6479.
K. Engeland, Cell. Death. Differ. 2022, 29, 946-960.
C. D. Bortner, N. B. E. Oldenburg, J. A. Cidlowski, Trends. Cell. Biol. 1995, 5, 21-26.
Q. Wang, L. Zhang, X. Yuan, Y. Ou, X. Zhu, Z. Cheng, P. Zhang, X. Wu, Y. Meng, L. Zhang, PLoS. One. 2016, 11, e0163327.
D. Westphal, R. M. Kluck, G. Dewson, Cell. Death. Differ. 2014, 21, 196-205.
T. Shien, H. Iwata, Jpn. J. Clin. Oncol. 2020, 50, 225-229.
A. G. Waks, E. P. Winer, JAMA. 2019, 321, 288-300.
Z. Y. Wang, L. Yin, Mol. Cell. Endocrinol. 2015, 418, 193-206.
S. Pernas, S. M. Tolaney, Ther. Adv. Med. Oncol. 2019, 11, 758835919833519.
R. Costa, A. N. Shah, C. A. Santa-Maria, M. R. Cruz, D. Mahalingam, B. A. Carneiro, Y. K. Chae, M. Cristofanilli, W. J. Gradishar, F. J. Giles, Cancer. Treat. Rev. 2017, 53, 111-119.

Auteurs

Harika Atmaca (H)

Department of Biology, Faculty of Science and Letters, Manisa Celal Bayar University, 45140, Manisa, Turkey.

Suleyman Ilhan (S)

Department of Biology, Faculty of Science and Letters, Manisa Celal Bayar University, 45140, Manisa, Turkey.

Buse Aysen Dundar (BA)

Department of Chemistry, Middle East Technical University, 06800, Ankara, Turkey.

Metin Zora (M)

Department of Chemistry, Middle East Technical University, 06800, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH